In Singapore’s humid climate, where respiratory illnesses can spread year-round, respiratory syncytial virus (RSV) is ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK on Wednesday unveiled promising topline Phase III data for a combo regimen of its RSV vaccine Arexvy and shingles shot ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.